NATCOPHARM.BONATCOPHARM.BOBSE
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
3Y CAGR+53.6%
5Y CAGR+9.7%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+53.6%/yr
vs -25.1%/yr prior
5Y CAGR
+9.7%/yr
Recent acceleration
Acceleration
+78.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.6x
Solid growth
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
202548.38%+10.6%
202443.74%+22.5%
202335.70%+167.2%
202213.36%-54.7%
202129.50%-3.0%
202030.40%-19.9%
201937.94%-10.5%
201842.42%+25.2%
201733.87%+31.5%
201625.75%-